Want to Retire Abroad? Here Are the Top 3 Spots for Americans. If you've ever dreamed of making a life in a foreign country, here's where you're likely to meet other Americans.
Henry Schein Highlights Dental Momentum, $125M Savings Goal Despite Medical Softness Henry Schein (
NASDAQ:HSIC ) executives said the company is seeing continued momentum in its dental business and remains committed to previously outlined operating improvement targets, while acknowledging softness in medical tied to a weaker respiratory illness season.
Speaking at a Bank of America h
What Lone Peak’s $20 Million Thermon Exit Could Signal After Record Earnings Thermon Group delivers industrial heating solutions worldwide, serving sectors from energy and transit to tech and manufacturing.
KBR Stock Has Fallen 45% This Past Year, but One Investor Just Disclosed a New $24 Million Bet This engineering and technology firm delivers mission-critical solutions to government and industrial clients worldwide.
Is Micron the Next Nvidia? Micron is having an Nvidia moment. That doesn't make it the next Nvidia.
ServisFirst Gets Axed by Champlain — a Minor Position in a Major Drawdown ServisFirst Bancshares delivers commercial and retail banking services across the Southeast with a relationship-driven approach.
Crafting title options within editorial guidelines An ETF Shop Just Made a Beaten-Down Medtech Its Top Holding Artivion delivers advanced cardiovascular and vascular solutions to healthcare providers worldwide through its proprietary medical devices.
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.
What Is the Cheapest "Magnificent Seven" Stock? There are two companies investors should consider for bargain values.
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
Horizon Quantum Computing Pte. Lays Out Quantum Software Push at Needham Conference Horizon Quantum Computing Pte. (
NASDAQ:HQ ) used its appearance at Needham & Company’s 21st annual Technology, Media, & Consumer Conference to outline its strategy as a newly public quantum software company focused on building infrastructure for developers, hardware providers and end users.
Needham
A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals Legend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies and solid tumors.
Nvidia Stock Is Poised to Rocket From the Booming Space Economy Nvidia dominates artificial intelligence (AI) on Earth – and it should do the same for AI in space.
With YMM Down 29%, First Beijing Bought 13 Million More Shares Full Truck Alliance is a top digital freight platform in China, connecting shippers and truckers through tech-enabled logistics services.
GDS Was Already Up 47% — Pinpoint Tripled Its Stake Anyway GDS Holdings develops and operates data centers in China, serving major cloud, internet, and financial sector clients.
Why Plug Power Stock Skyrocketed This Week Plug Power served up some promising news for investors this week.
Snapchat: Don't Rush to Buy This Social Media Stock Snap is unprofitable after almost 15 years and doesn't have the revenue growth rates of an exciting start-up.
M&G Shaved 2.4% of Methanex After a Near-Doubling Methanex supplies methanol worldwide, using integrated operations and its own fleet to serve industrial clients across major global markets.
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease.
Where Could Palantir Be in 10 Years? The Bull and Bear Cases. Palantir remains a high-variance AI infrastructure bet where narrative and execution will matter equally over the next decade.
